Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK14 | O94921 | 8/20 | 0.55 |
| ▸ | CCNY | Q8ND76 | 8/20 | 0.55 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.49 |
| ▸ | TYK2 | P29597 | 6/20 | 0.49 |
| ▸ | JAK1 | P23458 | 5/20 | 0.49 |
| ▸ | JAK2 | O60674 | 4/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1286749 | 0.88 | CDK14 (0.53) | CDK14CCNYMAPK7TYK2JAK1 | |
| SCHEMBL8212885 | 0.87 | TYK2 (0.68) | CDK14CCNYMAPK7TYK2JAK1 | |
| SCHEMBL954966 | 0.84 | CDK14 (0.55) | CDK14CCNYTYK2JAK1JAK2 | |
| SCHEMBL957511 | 0.82 | CDK14 (0.54) | CDK14CCNYTYK2JAK1JAK2 | |
| SCHEMBL13993632 | 0.82 | CDK14 (0.56) | CDK14CCNYTYK2JAK1JAK2 | |
| SCHEMBL954955 | 0.81 | KMT2A (0.51) | CDK14CCNYMAPK7TYK2JAK1 | |
| SCHEMBL8260751 | 0.81 | CDK14 (0.51) | CDK14CCNYTYK2JAK1JAK2 | |
| SCHEMBL23271061 | 0.81 | CDK14 (0.65) | CDK14CCNYTYK2JAK1JAK2 | |
| SCHEMBL13993636 | 0.81 | JAK2 (0.54) | CDK14CCNYTYK2JAK1JAK2 | |
| SCHEMBL959301 | 0.80 | POLB (0.56) | CDK14CCNYABL1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | ASTEX THERAPEUTICS LIMITED (UK) | 2008-12-11 | — | — | US | disclosed |
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | ASTEX THERAPEUTICS LIMITED (UK) | 2008-12-11 | — | — | US | disclosed |
| WO-2006077414-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | GSK3A, CDK11A, CDK1 | CDK14 8/4885CCNY 51/4885MAPK7 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.